• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

    9.460 +0.650 (+7.38%)
    Streaming Delayed Price Updated: 12:41 PM EDT, Jul 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 55,478
    Open 8.820
    Bid (Size) 9.450 (100)
    Ask (Size) 9.610 (100)
    Prev. Close 8.810
    Today's Range 8.810 - 9.680
    52wk Range 2.570 - 26.50
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
    From Turn Therapeutics, Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
    From Turn Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +101.7%
    +101.7%
    1 Month
    +87.1%
    +87.1%
    3 Month
    +169.5%
    +169.5%
    6 Month
    +103.4%
    +103.4%
    1 Year
    +35.1%
    +35.1%

    More News

    Read More
    News headline image
    Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
    From Turn Therapeutics, Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
    From Turn Therapeutics, Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
    From Turn Therapeutics, Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Appoints Arthur Golden to Board of Directors
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings ↗
    Via Benzinga
    Topics Stocks
    News headline image
    US Stocks Mixed; Nasdaq Falls Over 50 Points ↗
    Via Benzinga
    News headline image
    Stock Market Today: S&P 500, Nasdaq Futures Tumble As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta Air Lines, Levi Strauss In Focus ↗
    Via Benzinga
    Topics Economy Stocks

    Frequently Asked Questions

    Is Turn Therapeutics Inc. - Common Stock publicly traded?
    Yes, Turn Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Turn Therapeutics Inc. - Common Stock trade on?
    Turn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Turn Therapeutics Inc. - Common Stock?
    The ticker symbol for Turn Therapeutics Inc. - Common Stock is TTRX on the Nasdaq Stock Market
    What is the current price of Turn Therapeutics Inc. - Common Stock?
    The current price of Turn Therapeutics Inc. - Common Stock is 9.460
    When was Turn Therapeutics Inc. - Common Stock last traded?
    The last trade of Turn Therapeutics Inc. - Common Stock was at 07/10/26 12:41 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.